Rheumatoid arthritis
Conditions
Interventions
Denosumab/Alendronate Sodium Observation Group:None
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 75 years old; 2. Meet the diagnostic criteria for rheumatoid arthritis and osteoporosis; 3. Rheumatoid arthritis conforms to the 2010 ACR/EULAR classification criteria, and osteoporosis meets the dual-energy X-ray absorptiometry (DXA) test with BMD T value <= -2.5 in the lumbar spine or hip; 4. According to the doctor's assessment and the patient's willingness, initially receive denosumab or alendronate as the main anti-osteoporosis treatment (calcium and vitamin D can be used as the basic treatment); 5. Voluntarily sign the informed consent form
Exclusion criteria
Exclusion criteria: 1.Have other diseases that severely affect bone metabolism (such as hyperparathyroidism, Paget's disease of bone, osteomalacia); 2.have clear contraindications to using denosumab or alendronate (such as severe renal insufficiency with eGFR < 35 mL/min, hypocalcemia, active upper gastrointestinal diseases, planned invasive dental surgery, jaw necrosis, etc.); 3.have used other potent anti-osteoporosis drugs (such as bisphosphonates, denosumab, teriparatide, etc.) within 1 year before the study; 4.are pregnant or planning to become pregnant, or are breastfeeding; 5.have mental or cognitive impairments and are unable to cooperate in completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lumbar vertebrae bone mineral density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum markers of osteoporosis;Femoral neck bone density;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactWang Hai
Yuebei People’s Hospital
Outcome results
None listed